March 31, 2026

Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029.

Highlights:

- Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic ("IVD") development and supporting U.S. clinical validation activities.
- Virax is also evaluating potential U.S. laboratory-based testing service offerings, which may include a laboratory-developed test ("LDT") pathway.

Within the scope of approval, ISO 13485:2016 covers the design and development of immunological assay components and kits, including antibody- and peptide-based reagents, for IVD applications. Within the scope of approval, ISO 9001:2015 covers the provision of manufacturing, design and development of Virax's research-use-only products and services.

ISO 13485 and ISO 9001 are internationally recognised quality management standards that establish a framework for design control, risk management, traceability, supplier qualification and manufacturing consistency. In simple terms, ISO 13485 is a widely used quality standard for medical devices and diagnostics, while ISO 9001 is a broader quality management standard used across many industries. Virax believes these certifications strengthen the controls and documentation needed to advance regulated diagnostics programmes and support clinical validation work.

Virax believes these certifications provide an important operational foundation for the Company's quality-managed development activities, including its in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as post-acute sequelae of SARS-CoV-2 ("PASC") (commonly referred to as "Long COVID"), and support the Company's broader strategy to build a T cell immune-profiling platform with a transatlantic clinical and regulatory footprint.

In parallel, Virax continues to advance its U.S. clinical validation work, which the Company believes is supported by a strengthened quality framework. As previously disclosed, Virax

has entered into a Research Services Agreement ("RSA") with Emory University's ADJUST Center to conduct clinical studies of ViraxImmune™ focused on immune profiling in individuals with PASC (commonly referred to as "Long COVID"). Under the agreement, Emory will conduct laboratory testing and analysis to generate clinical data intended to inform Virax's regulatory planning and potential future commercial rollout.

Virax believes strengthening its quality systems is relevant to disciplined development and control of key assay components and supporting documentation processes, which can support validation activities and scale-up planning, subject to applicable regulatory requirements.

"*Achieving ISO 13485 and ISO 9001 certification is a meaningful milestone for Virax*," said James Foster, Chairman and Chief Executive Officer of Virax Biolabs. "*It reflects the work our team has done to implement robust quality systems that support the regulated development of our immunological assays. This matters as we continue to execute our PAIS strategy, including strengthening the foundation for regulated IVD development and expanding our evidence base through UK and U.S. clinical programmes, while also evaluating potential U.S. laboratory-based testing pathways, which may include an LDT route*."

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is developing T cell-based test technologies with the intention of providing an immunology profiling platform. T cell testing can be particularly effective in the diagnosis and therapeutics of post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

For more information, please visit www.viraxbiolabs.com

Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms.

In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time

by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us.

These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-achieves-iso-certifications-laying-foundation-for-regulated-ivd-development-and-us-clinical-validation-302727405.html

SOURCE Virax BioLabs Group Limited